FINANCIAL PERIOD DATA REFRESH REQUIRED
Select the Refresh button on the Summary or Disclosure tab
Registration number:
Drug Tariff Pro Ltd
for the Period from 23 April 2024 to 30 April 2025
Drug Tariff Pro Ltd
(Registration number: 15673972)
Balance Sheet as at 30 April 2025
|
Note |
2025 |
|
|
Fixed assets |
||
|
Tangible assets |
|
|
|
Current assets |
||
|
Debtors |
|
|
|
Cash at bank and in hand |
|
|
|
|
||
|
Creditors: Amounts falling due within one year |
( |
|
|
Net current liabilities |
( |
|
|
Net assets |
|
|
|
Capital and reserves |
||
|
Called up share capital |
|
|
|
Retained earnings |
|
|
|
Shareholders' funds |
|
For the financial period ending 30 April 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
|
• |
|
|
• |
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts. |
These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Director's Report and the Profit and Loss Account has been taken.
.........................................
C J Armstrong
Director
Drug Tariff Pro Ltd
Notes to the Unaudited Financial Statements for the Period from 23 April 2024 to 30 April 2025
|
Accounting policies |
Statutory information
Drug Tariff Pro Ltd is a private company, limited by shares, domiciled in England and Wales, company number 15673972. The registered office is at Farrier's Barn, 5 Castle Farm, Ladyfield Road, Thorpe Salvin, S80 3JN.
Summary of significant accounting policies and key accounting estimates
The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.
Statement of compliance
These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.
Basis of preparation
These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value. The presentation currency is United Kingdom pounds sterling, which is the functional currency of the company. The financial statements are those of an individual entity.
Turnover
Turnover comprises the fair value of the consideration received for the provision of services in the ordinary course of the company's activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts. Turnover is recognised in line with service periods and subscriptions.
Tax
The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.
The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in countries where the company operates and generates taxable income.
The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.
Tangible assets
Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.
Drug Tariff Pro Ltd
Notes to the Unaudited Financial Statements for the Period from 23 April 2024 to 30 April 2025 (continued)
|
1 |
Accounting policies (continued) |
Depreciation
Depreciation is charged so as to write off the cost of assets over their estimated useful lives, as follows:
|
Asset class |
Depreciation method and rate |
|
Office equipment |
25% straight line per annum |
|
Staff numbers |
The average number of persons employed by the company (including the director) during the period, was
|
Tangible assets |
|
Office equipment |
|
|
Cost |
|
|
Additions |
|
|
At 30 April 2025 |
|
|
Depreciation |
|
|
Charge for the period |
|
|
At 30 April 2025 |
|
|
Carrying amount |
|
|
At 30 April 2025 |
|
|
Debtors |
|
2025 |
|
|
Prepayments |
|
|
Other debtors |
|
|
|
Drug Tariff Pro Ltd
Notes to the Unaudited Financial Statements for the Period from 23 April 2024 to 30 April 2025 (continued)
|
Creditors |
|
2025 |
|
|
Due within one year |
|
|
Taxation and social security |
|
|
Accruals and deferred income |
|
|
|
|
Related party transactions |
During the year the director had an interest free loan with the company. At the balance sheet date the amount due to the company was £1,000.